在纤维化间歇性肺部疾病中的预测性治疗策略的基因组分析
Fabio Perrotta1,2, Stefano Sanduzzi Zamparelli3, Vito D'Agnano1,2
1Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", 80131 Naples, Italy.
Biomedicines
|July 27, 2024
概括
基因组签名可以识别患有纤维化间歇性肺部疾病 (f-ILDs) 的患者,这些患者有进展风险. 药物基因组学也会影响肺纤维化的抗纤维素和免疫调节疗法的治疗反应.
科学领域:
- 肺部病理学 肺部病理学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 异形性肺纤维化 (IPF) 是渐进性纤维化间歇性肺病 (f-ILDs) 的一个模型.
- 其他f-ILDs,包括那些与自身免疫性疾病,类菌病和过敏性肺炎相关的,也可以表现出疾病的进展.
- 识别渐进性表型对于患者管理至关重要.
研究的目的:
- 审查基因组特征在识别渐进性f-ILD表型中的作用.
- 探索药物基因组学对抗纤维菌和免疫调节治疗疗效和安全的影响.
- 讨论目前的研究和肺纤维化疾病的未来方向.
主要方法:
- 对IPF和其他f-ILDs现有的文献进行叙述性审查.
- 对将基因组数据纳入临床实践的研究进行分析.
- 检查与治疗反应相关的药物基因组数据.
主要成果:
- 基因组签名在预测f-ILDs疾病进展方面表现有前途.
- 药物基因组学越来越多地被认为对抗纤维菌和免疫调节治疗结果的影响.
- 系统性自身免疫性疾病,肉类粉症和过敏性肺炎是相关的f-ILD背景.
结论:
- 整合基因组信息可以为f-ILD患者个性化风险评估和治疗策略.
- 药基因组学的洞察对于优化抗纤维菌和免疫调节疗法至关重要.
- 需要进一步的研究,才能充分利用基因组学来管理渐进性肺纤维化.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


